Further Observations on the Inhibitory Effect of Myxoviruses on a Transplantable Murine Leukemia

Complement-dependent antiviral monospecific antibody-mediated lysis of murine cells coated with Sendai virus or its envelope component

“…However, this CDAMC was different from that of fusion-positive virus-coated cells in that it occurred with only anti-F serum, but not with both anti-F and anti-HN sera. DISCUSSION There have been several reports (3,4,6,22) This finding seems to be consistent with the result that in the presence of rabbit complement both anti-HA and anti-hemolysin sera were cytotoxic to cells chronically infected with measles virus (5). The capability of Sendai visions to induce CDAMC susceptibility with anti-F and anti-HN sera was found to be invariably associated with fusion activity.…”

Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions

“…Promising results were noted in preclinical models of leukemia, lymphoma, melanoma, neuroblastoma, fibrosarcoma, rat pheochromocytoma, colon carcinoma, lung carcinoma, prostate carcinoma, breast carcinoma, gastric carcinoma, mesothelioma, and head and neck carcinoma [7,9,12,13,26,27,31,34–36,56,59,68,70,77,92,107,108,122–128]. Clinical studies that followed consisted of NDV-based tumor vaccines and direct administration of naturally-occurring NDV to patients with advanced cancers and in post-operative setting.…”

“…Development of cell and virus culture techniques in the early 1950’s led to intensive exploration of virus therapy in small animal tumor models and eventually in humans[2]. Due to significant virulence associated with the use of some of the human pathogens, animal viruses were explored as an alternative, with Newcastle Disease Virus (NDV) becoming a promising oncolytic agent [3–13]. This review will summarize the developments in the field of NDV cancer therapy, including the delineation of the mechanism of its oncolytic specificity, clinical trials, and recent advancements with the advent of genetic engineering.…”

Antibody mediated complement dependent lysis of virus infected cells

“…For example, passively administered antibody binds to virus infected targets in vivo and/or initiates cellular necrosis and tissue injury [13,21,38,46,50], and C depletion lessens the severity of tissue injury and disease [19,38,39]. Virus infected cells can be destroyed by host immune responses that limit the spread of virus infection and aid in the host's recovery.…”